{
    "medicine_id": "02a37884fb48f01ced8f33c7a3792054d391584a",
    "platform_id": "DB05779",
    "metadata": {
        "name": "Kadcyla 160 mg Powder for solution",
        "composition": "160 mg Oglufanide",
        "clinical_particulars": {
            "therapeutic_indications": "Investigated for use treatment in hepatitis viral C",
            "contraindications": {
                "disease": "NA",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Oglufanide regulates the body s innate immune response to defeat invading germs and cancer cells It may control or reverse the suppression of the immune system which the hepatitis virus uses to defeat our normally healthy defenses",
                "excipients": "NA",
                "incompatibilities": [
                    {
                        "drugbank-id": "DB00012",
                        "description": "The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Oglufanide"
                    },
                    {
                        "drugbank-id": "DB00016",
                        "description": "The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Oglufanide"
                    },
                    {
                        "drugbank-id": "DB08894",
                        "description": "The risk or severity of Thrombosis can be increased when Peginesatide is combined with Oglufanide"
                    },
                    {
                        "drugbank-id": "DB09107",
                        "description": "The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol epoetin beta is combined with Oglufanide"
                    }
                ]
            }
        },
        "revision_date": "2023-05-14"
    }
}